Mariner
NBSE

Mariner’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Mariner’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-775
Closed -$3K – 2953
2023
Q1 		$3K Hold
775
– – ﹤0.01% 2773
2022
Q4 		$3K Hold
775
– – ﹤0.01% 2732
2022
Q3 		$6K Buy
+775
New +$12.8K ﹤0.01% 2428

Other funds holding NBSE

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner's NBSE Position: Q2 2023 in Review

Mariner sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 775 shares — an estimated $3K sold.

Mariner first reported a position in NBSE in Q3 2022 and held it in 3 quarters. The position peaked at $6K in Q3 2022. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

  • Mariner reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Mariner sold 775 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3K.
  • Mariner first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Mariner's NeuBase Therapeutics, Inc. Common Stock position peaked at $6K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Mariner's 13F filing for Q2 2023, filed 11 Aug 2023.